Description: |
Vandetanib (Zactima) is a VEGFR and EGFR antagonist and a tyrosine kinase inhibitor that has been approved by the FDA for use in medullary thyroid cancer. The purpose of this investigational study is to better understand how vandetanib affects humans who have kidney cancer related to von Hippel-Lindau (VHL) disease. Every 12 weeks, computerized tomography (CT) or magnetic resonance imaging (MRI) scans will be done to assess the size of participants' tumors. Participants whose tumors do not grow and who do not have unacceptable side effects may continue to receive vandetanib to maintain the current condition. The primary outcome measure is overall response rate. |
Link: |
|
Site: |
NCI |
Principal Investigator: |
W. Marston Linehan |